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On the basis of the benefits of antihypertensive treatment,
progressively intensive treatment is advocated. However,
it remains controversial whether intensive blood pressure
control might increase the frequency of serious adverse
events (SAEs) compared with moderate control. This
review assessed the occurrence of SAEs in blood pressure
treatment with predefined blood pressure targets. Seven
original studies and eight post hoc analyses (derived from
two original studies) met the inclusion criteria. Compared
with moderate blood pressure treatment, intensive
treatment was associated with a significant increase in
treatment-related SAEs (Sign-test: P¼0.0002, Wilcoxon
signed-rank test: P¼ 0.001). However, comparability
between studies was limited, due to unclear
determinations about the treatment-relatedness of adverse
events, missing definitions of SAEs and variations in
recording methods. Thus, a meta-analysis was not justified.
The definitions of serious adverse events and methods of
recording and reporting need to be improved and
standardized to facilitate the comparison of results.
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Controllo della Pressione Arteriosa SIStolica; CDK, Chronic
kidney disease; eGFR, estimated glomerular filtration rate;
ICH, International Conference on Harmonisation of
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Intervention Trial; SPS3, Secondary Prevention of Small
Subcortical Strokes Trial; VALISH, Valsartan in Elderly
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INTRODUCTION
W
orldwide, arterial hypertension affects about
1.39 billion people [1]. The diagnosis of high
blood pressure is often delayed, due to its
typically asymptomatic course. Arterial hypertension is
the most common modifiable risk factor of death in men,
and the second most common in women. Untreated hyper-
tension increases the risk of ischemic, coronary and hyper-
tensive heart diseases; ischemic and haemorrhagic stroke;
and chronic kidney disease [2,3]. The risk of a cardiovascu-
lar event with systolic hypertension is highly correlated
with age. The prevalence rises with increasing age, up to
60–70% among individuals over 60 years old [4].
Antihypertensive therapy reduces the risk of cardiovas-
cular and cerebrovascular events [5–7]. However, a relevant
issue in hypertension treatment is the difficulty in deter-
mining the degree of blood pressure lowering. Extensive
meta-analyses have suggested that ‘the lower [the blood
pressure], the better’ [8]. Large-scale trials that investigated
the efficacy of lowering blood pressure showed that risk
could be reduced by up to 22% for coronary heart disease
and 40% for stroke, with a 10-mmHg reduction in blood
pressure [9,10]. However, defining the optimal blood pres-
sure target range is challenging, because the effect on risk
follows a ‘J-shaped curve’, wherein more harm than benefit
is incurred at very low blood pressure levels [11–13].
In 2017, the American College of Cardiology/American
Heart Association (ACC/AHA) recommended that the target
blood pressure should be below 130/80 mmHg, except in
patients who require secondary stroke prevention and
patients with low cardiovascular risk; in the latter cases,
a target level of less than 140/90mmHg was advised [14].
Lower blood pressure targets require an extensive therapy
regime, and the risk of adverse events increases [15].
Adverse events can be a direct effect of the antihypertensive
agent (e.g. angioedema, cough, rash) or a consequence
of low blood pressure (e.g. hypotension, syncope). Anti-
hypertensive treatment in the older population is
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particularly challenging, due to comorbidity, frailty, poly-
pharmacy and cognitive impairments. In this population, a
single serious adverse event, such as a syncope, could have
major consequences; thus, a very strict blood pressure-
regime might not be adequate, and higher blood pressure
levels can be tolerated [14]. Few meta-analyses have
focused on the frequencies of adverse events at different
blood pressure targets [7,16,17].
In this review, we analysed results from randomized
studies to assess the frequencies of various serious adverse
events associated with blood pressure target-level oriented
therapies.
MATERIALS ANDMETHODS
This systematic review was designed according to the
‘Preferred Reporting Items for Systematic Reviews and
Meta-Analyses’ (PRISMA) [18].
Literature search
In April 2018, a systematic literature search was conducted
by an experienced librarian (M.G.) at Careum Bibliothek of
the University of Zurich. The following six databases were
included: MEDLINE (via Ovid), EMBASE, Cochrane Library,
Web of Science, Scopus and Pool. The search terms used
were ‘intensive, strict, aggressive, tight, standard, moderate
blood pressure control’, ‘target blood pressure’, ‘adverse
events’ and ‘side-effects’. A detailed description of one
search strategy is shown in Supplementary Table 1,
http://links.lww.com/HJH/B119. No search limitations
were applied, in terms of the type of study, publication
date or language. Reference lists from reviews and meta-
analyses were manually scanned to identify any other
relevant studies.
Inclusion criteria
We included randomized trials that compared the results
between two groups of patients with hypertension that had
different blood pressure targets. Eligible studies had to
include at least 30 patients with arterial hypertension aged
18 years or older, and they had to assess target-oriented
blood pressure treatment that consisted of various pharma-
cological agents, given at various dosages, and the doses
were titrated until the patient achieved the target blood
pressure levels.
Studies that compared antihypertensive agents or differ-
ent dosages were excluded when they lacked predefined
blood pressure targets, quantification of adverse events
or baseline characteristics. Furthermore, studies were
excluded when they focused on secondary antihyperten-
sive treatments (e.g. bariatric surgery, diet, reduced salt
intake), blood pressure treatment in emergency situations
(e.g. intracerebral haemorrhage, pregnancy, hypertensive
emergency) or treatment in perioperative settings. Trials
were excluded when they assessed cotreatments in addi-
tion to antihypertensive treatment (e.g. treatments for
diabetes mellitus, dyslipidaemia) with defined targets
[e.g. HbA1c <7%, low-density lipoprotein (LDL)-level
<1.8mmol/l], due to the lack of a clear association between
adverse events and the antihypertensive treatment.
Study selection
The identification of eligible publications, data extraction
and quality assessments were conducted independently by
two authors (LF and JB). All references were initially
screened for relevance, based on the title and abstract,
by two reviewers (LF and JB). Finally, full text analyses
were performed to determine eligibility. Disagreements
were discussed and resolved by consensus or with third
party arbitration (JS).
Quality assessment
We used the checklist of the Scottish Intercollegiate Guide-
lines Network (SIGN) for randomized controlled trials
(RCTs) [19] to assess the quality of included RCTs. Study
quality criteria included proper randomization conduct,
treatment allocation concealment, similarity of treatment
groups at baseline, a description of study eligibility criteria,
completed follow-up, bias minimization and the use of an
intention-to-treat analysis. A high-quality rating was given
when the majority of criteria were fulfilled and further
research would have been unlikely to contradict study
results; an acceptable quality rating was given when most
criteria were met with a few flaws, and future research
might reduce the certainty of the conclusions. A low-quality
rating was given when either most criteria were not met or
significant flaws were present in key aspects of the
study design.
Data extraction
For each trial, standard information was extracted into a
Microsoft Excel (2016) spreadsheet (Microsoft Corporation,
Redmond, Washington, USA). The standard data included
baseline patient characteristics [age, sex, BMI, smoking
status, mean SBP and DBP, history of diabetes, estimated
glomerular filtration rate (eGFR), history of cardiovascular
event, statin use], blood pressure targets in each study arm,
the follow-up duration, the mean SBP and DBP during the
trial, outcome events and serious adverse events.
Definition of moderate and intensive treatment
We defined in each study ‘moderate’ as the treatment group
with the higher SBP target and the ‘intensive’ as the lower
SBP target.
Outcomes
The outcomes of interest were the frequency of adverse
events, particularly serious adverse events, during antihy-
pertensive treatment with different blood pressure targets.
According to the Working Group of the International Con-
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH, doc-
ument E2A), a serious adverse event was defined as a
harmful side effect that is fatal or life threatening, results
in clinically significant or persistent disability, or requires or
prolongs hospitalization [20]. Because a ‘side effect’ sug-
gests causality between a treatment and a harmful event,
which can rarely be confirmed, the term ‘adverse event’ was
more suitable, according to a recommendation from the
CONSORT Statement extension [21].
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Statistical analysis
The primary objective of this study was to assess the
frequency of adverse events during pharmacological treat-
ments for arterial hypertension that targeted predefined
blood pressure levels. We analysed all adverse events
and treatment-related adverse events. Because most sec-
ondary studies (i.e. secondary analyses from original stud-
ies) were derived from the Systolic Blood Pressure
Intervention Trial (SPRINT) [6], the results were not inde-
pendent, due to the partially overlapping patient sub-
groups; thus, a meta-analysis would not have been
justified. Therefore, we performed only descriptive and
comparative analyses to summarize findings across all
studies. The nonparametric Sign-test and Wilcoxon
signed-rank test were performed to compare distributions
of adverse events between intensive and moderate treat-
ment groups. The Wilcoxon signed-rank test takes into
consideration the magnitude of the difference between
population means.
Our secondary objective was to identify potential sub-
groups that were at an increased risk of serious adverse
events, based on secondary studies that analysed the pop-
ulation from the SPRINT study [6].
All analyses were performed with R statistical software
(R Core Team, Vienna, Austria) [22].
RESULTS
Study selection
Our systematic literature search yielded 1805 studies, and
932 remained after removing duplications (Fig. 1). Checking
the reference lists of identified studies revealed 11 additional
publications; therefore, we assessed a total of 943 studies for
title and abstract relevance.On the basis of relevant titles and
abstracts, we assessed 65 publications in detail and applied
all inclusion and exclusion criteria. The main reasons for
exclusion are shown in Fig. 1. Finally, 15 studies were
included in the present review. A quality assessment of
the studies did not lead to any other exclusions.
Overview of included studies
Of the 15 included studies, six were original trial reports
[6,23–27] and nine were secondary analyses [28–36]. One
of the secondary analyses describes a trial whose original
report (Japanese Trial to Assess Optimal Systolic Blood
Pressure in Elderly Hypertensive Patients, JATOS [37])
was excluded due to insufficient quantitative data. Conse-
quently, we treated the secondary per-protocol analysis
(JATOSpp [28]) of that trial as an original study, due to an
extensive analysis of serious adverse events.
The characteristics of the included seven original studies
are summarized in Table 1. All studies were conducted in an
outclinic setting with patients who were not institutional-
ized, and all studies were published between 2002 and
2015. The mean participant age ranged from 54 to 76 years,
and follow-up periods ranged between 2 and 4.7 years. The
follow-up in the SPRINT study lasted until August 2015; the
trial was terminated early, due to significant interim results
that favoured the intensive intervention [6]. In the different
study arms, the SBP targets varied between 120 and
160mmHg.
Eight secondary studies were included that were posthoc
analyses of the original studies. Of these secondary studies,
sevenwere derived from the SPRINT study [30–36], and one
was derived from the Action to Control Cardiovascular Risk
in Diabetes trial (ACCORD) [29]. Baseline characteristics are
described in Table 1.
Characteristics of original studies
Only some studies considered whether adverse events
were treatment related. The SPRINT trial reported all
adverse events together, and then separately studied pos-
sible treatment-related and definite treatment-related
groups [6]. The ACCORD [24] and Secondary Prevention
of Small Subcortical Strokes Trial (SPS3) [26] trials only
reported adverse events that were possibly related to anti-
hypertensive treatment. No information concerning treat-
ment relatedness was provided in the African American
Study of Kidney Disease and Hypertension (AASK) [23] or
JATOSpp [28] study. None of the trials documented the
same set of adverse events.
Methods for recording serious adverse events varied
between studies (Table 1). Five studies [6,23–25,27] used
clinic visits for recording serious adverse events, two of
them conducted a structured interview [6,23]. In two stud-
ies, no details were available about the recording method
[26,28]. After titrating the medication to achieve the target
blood pressure, the frequency of clinic visits were set to at
least once a month [23,24,26], at least every 2 months [6],
every 3 months [27], every 4 months [25] and at least two
times per year [28]. More information about the reviewed
studies is provided in Supplementary Tables 3 and 4, http://
links.lww.com/HJH/B119.
To achieve predefined blood pressure targets, all studies
used a treatment algorithm. The algorithm prescribed the
dose titration and the addition of drugs, based on a stepwise
approach. The choice of agents in each pharmaceutical
class was determined by the trial investigators. In the AASK
trial [23], participants were randomized to a b-blocker
(metoprolol), angiotensin-converting enzyme inhibitor
(ramipril) or the dihydropyridine calcium channel blocker,
amlodipine, but further open-label agents were added to
achieve the target blood pressures. On the contrary, the
JATOSpp [28] and Valsartan in Elderly Isolated Systolic
Hypertension Study (VALISH) [27] trials started with efoni-
dipine or valsartan, followed by dose titration, and then
other agents were added.
We compared the changes in blood pressure due to the
different treatment regimes employed in the reviewed
studies (Fig. 2). For example, in the ACCORD study, the
target values were 120 and 140mmHg for intensive and
moderate treatments, respectively. The mean baseline
systolic pressures were 130.0 and 139.4mmHg, respec-
tively. The mean blood pressures achieved were 119.3
and 133.5mmHg, respectively. However, the achieved
blood pressures were measured differently among studies.
One study measured the postbaseline average over 3
months [23] and other studies measured blood pressure
after 1 year of follow-up [6,24–28]. Only four studies
[24,26–28] actually achieved the predefined target in
the intensive treatment group after 1 year of target-
oriented treatment.
Adverse events in hypertension treatment
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Definition of serious adverse events
Only the ACCORD [24] and SPRINT [6] studies provided a
definition of serious adverse events that conformed to the
definition from the ICH Working Group [20]. All the other
studies had unclear definitions of serious adverse events
(Supplementary Table 3, http://links.lww.com/HJH/B119).
Moreover, often, each particular serious adverse event
was either not clearly defined or not reported. In the
SPRINT study [6], hypotension was defined as a
FIGURE 1 Flowchart of study selection. AE, adverse event(s); BP, blood pressure; SAE, serious adverse event(s).
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BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ER, emergency room; int., intensive antihypertensive treatment; mod., moderate
antihypertensive treatment; NR, not reported; SD, standard deviation.
aMean arterial pressure; alternative values for follow-up periods.
bMean.
cMean for falls/fractures.
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symptomatic low blood pressure without specific blood
pressure cut-offs; syncope was a sudden temporary loss of
consciousness; and an injurious fall was a fall that resulted
in either an emergency department evaluation or hospitali-
zation. Acute kidney injury (AKI) was reported when it was
listed in the hospital discharge summary or noted in the
emergency department [6]. In the VALISH study [27], an AKI
was defined as a doubling of serum creatinine to a level
more than 2.0mg per 100ml or the introduction of dialysis.
Frequency of serious adverse events in original
studies
Table 2 summarizes the serious adverse events in original
studies reported for the corresponding treatment groups.
The frequencies of adverse events variedgreatly between the
different studies. In studies wherein the serious adverse
events were attributed to treatment [6,24,26], a significantly
higher rate of serious adverse events was related to intensive
blood pressure therapy compared with moderate therapy
(Sign-test:P¼ 0.0002,Wilcoxon signed-rank test: P¼ 0.001).
In studies that did not differentiate between treatment-
related and nontreatment-related serious adverse events
[6,25,27], a significant increase in serious adverse events
was notedwith intensive treatment comparedwithmoderate
treatment, when the rates of serious adverse events were
comparedwith theWilcoxon-test (P¼ 0.01), but notwith the
Sign Test (P¼ 0.12).On the contrary, in studies that provided
no information about the relationship between serious
adverse events and antihypertensive treatment [23,28], no
significant difference in adverse events was observed
between the intensive and moderate treatment groups
(Sign-test: P¼ 1.0, Wilcoxon signed-rank test: P¼ 0.13).
In the groups with intensive blood pressure treatment,
the rates of dizziness varied from 0.1% [28] to 53.4% [23] and
FIGURE 2 Comparison of target and achieved blood pressures results from seven studies. Arrows show the changes in systemic blood pressure with moderate (grey) and
intensive (black) treatments. The beginning of each arrow indicates the baseline mean SBP; the tip of each arrow demonstrates the achieved mean SBP. Horizontal lines
are the targeted values. The AASK trial target values are not illustrated, because the targets were expressed for the mean arterial pressure, rather than the SBP.












ACCORD [24] int. Yes 43.3 0.7 0.5 – – 23.8 0.3 3.1 – –
(n¼4733) mod. Yes 40.3 0.0 0.2 – – 15.5 0.2 3.0 – –
SPS3 [26] int. Yes 21.6 – 0.7 0.2 – – – – – –
(n¼3020) mod. Yes 20.0 – 0.3 0.0 – – – – – –
Cardio-Sis [25] int. No 0.4 0.9 – – – 0.2 – – 2.5 –
(n¼1111) mod. No 0.7 0.4 – – – 0.2 – – 1.3 –
AASK [23] int. – 53.4 – 6.3 – – – 3.5 0.0 54.6 –
(n¼1094) mod. – 49.0 – 5.2 – – – 5.4 0.7 47.0 –
JATOSpp [28] int. – 0.1 – – – 0.5 – – – – –
(n¼2722) mod. – 0.5 – – – 0.6 – – – – –
SPRINT [6] int. Yes – 2.7 2.0 0.8 – 2.1 – 3.8 – 1.1
(n¼9361) mod. Yes – 1.2 0.9 0.5 – 0.8 – 3.7 – 0.6
SPRINT [6] int. No – 3.4 3.5 7.1 – 4.4 – – – 2.2
(n¼9361) mod. No – 2.0 2.4 7.1 – 2.6 – – – 1.8
VALISH [27] int. No – – – – – 0.3 – – – –
(n¼3079) mod. No – – – – – 0.1 – – – –
–, not reported; AKI, acute kidney injury; attr., attributable to antihypertensive treatment; int., intensive antihypertensive treatment; mod., moderate antihypertensive treatment.
Frey et al.
2140 www.jhypertension.com Volume 37  Number 11  November 2019
hypotension, syncope and injurious falls occurred more
commonly than fractures. It was difficult to compare groups
in terms of AKI, due to nonuniform definitions and varying
frequencies. The ACCORD trial [24] defined AKI in terms of
absolute creatinine elevations (>1.5mg/dl in men,
>1.3mg/dl in women). In contrast, the SPRINT trial [6]
determined acute kidney injuries, based on hospital dis-
charge summaries and emergency reports. Nevertheless,
higher rates of renal events were observed among patients
who received intensive treatment compared with patients
who receivedmoderate treatment. Varying results related to
the frequency of coughing were observed in the CARDI-
Ovascolari del Controllo della Pressione Arteriosa SIStolica
(Cardio-Sis) and AASK studies [23,25]. Additional details
about serious events are shown in Supplementary Table 5,
http://links.lww.com/HJH/B119.
Frequency of serious adverse events in
secondary studies
Results from secondary studies are illustrated in Supple-
mentary Table 6, http://links.lww.com/HJH/B119. Gener-
ally, the secondary studies reported increased rates of
serious adverse events associated with intensive treatment.
Most studies reported about AKI, and except for Obi et al.
[34] and Margolis et al. [29], all reported about hypotension,
syncope, injurious falls, bradycardia and electrolyte abnor-
malities. Further, there is some evidence to suggest that
intensive treatment had lower risk of injurious falls, espe-
cially among patients aged more than 75 years. Beddhu
et al. [30] reported a significant higher risk for incident of
chronic kidney disease (reduction in eGFR of at least 30%
with a confirmed level less than 60ml/min/1.73m2) in the
intensive treatment group.
Risk of bias
The assessment of the risk of bias, based on the SIGN
Checklist for randomized controlled studies, is shown in
Supplementary Table 2, http://links.lww.com/HJH/B119.
All studies were at least acceptable in their effort to mini-
mize bias; therefore, no study was excluded. No study
implemented blinding of individuals or investigators; thus,




This study reviewed the results of seven randomized origi-
nal trials with 25 120 participants to assess adverse effects of
treatments with different blood pressure targets. We found
that serious adverse events significantly increased in treat-
ments with lower blood pressure targets. Despite the car-
diovascular benefit, intensive antihypertensive treatment
was associated with significantly elevated frequencies of
dizziness, syncope, AKI and hypotension compared with
moderate antihypertensive treatment. In secondary studies,
the risk of injurious falls did not appear to be associated
with more intensive blood pressure treatment; this is in
contrast to the results for all other types of serious adverse
events. A meta-analysis of the results was not feasible, due
to methodological heterogeneity among the original
studies. These studies used different definitions of adverse
events; different methods of recording adverse events;
different blood pressure targets; variable follow-up times;
and diverse study populations.
Comparison to existing literature
To the best of our knowledge, this is the first systematic
review to present data on the entire spectrum of serious
adverse events reported in studies that evaluated the ben-
efits and adverse events between moderate and intensive
blood pressure treatment modalities. Previous publications
performed limited investigations of the benefit–harm ratio
of antihypertensive treatments. They only compared the
rate of cardiovascular events and the total number of all
serious events [16,17], or they analysed only specific
adverse events (e.g. syncope, hypotension, falls, cognitive
outcome or acute kidney injuries) [7,29,38,39]. Weiss et al.
[7] and Sink et al. [39] confirmed the associations between
low blood pressure targets and increased risks of hypoten-
sion, syncope and a higher medication burden. In a meta-
analysis from Bangalore et al. [16], the risk of any serious
adverse event was elevated in patients with low blood
pressure targets (<120 and <130mmHg), compared with
those with higher targets, but they did not specify the rates
of particular serious adverse events.
To date, age has not been associated with an increase in
the risk of serious adverse events in antihypertensive ther-
apy. However, serious adverse events have been reported
to be insignificantly higher in older than in younger indi-
viduals [36]. Other risk factors associated with an increase in
adverse effects with antihypertensive treatment have
included smoking, statin treatments, elevated creatinine
and lipid levels [15], elevated pulse pressure [40] and a
high visit-to-visit variability in DBP [41]. Therefore, estab-
lishing individualized blood pressure targets, based on
patient characteristics, seems reasonable, as suggested by
Patel et al. [42].
The amount of effort that should be directed towards
achieving low blood pressure targets remains a controver-
sial issue, particularly for older and frail patients. Possible
adverse events, poly-pharmacy, variable life expectancy,
cognitive impairment and a high degree of heterogeneity in
comorbidity are factors to consider, according to the 2017
Guidelines of the American Heart Association/American
College of Cardiology [14].
Implications for further research
This review demonstrated that there are shortcomings in
the definitions, the recording methods and the reporting of
serious adverse events. These limitations have made it
difficult to interpret and compare the results among studies,
particularly the benefit-to-harm ratios.
In general, the majority of all included studies lacked a
definition of serious adverse events. Distinct definitions of
serious adverse events were only given in two original
studies [6,24]. Definitions of specific serious adverse events
were provided in the SPRINT study [6] for two adverse
events (i.e. AKI and injurious fall), and in the VALISH study
[27] for one adverse event (i.e. AKI). A definition of hypo-
tension with cut-off values was not reported in any included
study. The SPRINT trial just encoded hypotension as
Adverse events in hypertension treatment
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symptomatic low blood pressure, but they did not specify
low blood pressure cut-offs or symptoms [39]. Nonuniform
definitions of individual adverse events and nonuniform
documentation methods lead to heterogeneity in the rates
and types of reported adverse events. Improved thorough-
ness in recording and reporting adverse events will most
likely lead to higher frequencies of serious adverse events.
For example, the rates of dizziness in two studies [23,26]
were 0.1 and 53.4%; this large difference was difficult to
explain, but it was probably due to more than one issue in
methodology. Moreover, we expect that a method of
explicitly asking each participant to report adverse events,
similar to the method applied in the AASK Trial [23], would
most likely result in high rates of serious adverse events.
It was difficult to determine whether an event was
related to the antihypertensive treatment; this judgement
was made by the trial investigators. No data were provided
in any of the included studies that related to making this
decision. Two studies provided no information on whether
the reported adverse events were treatment related [23,28].
Reporting a discontinuation or change in treatment as a
consequence of serious adverse events would be relevant
information for physicians.
Future research in the field of target-oriented blood
pressure treatment should be conducted with precisely
defined outcome(s) and standardized methods for record-
ing serious adverse events. On the basis of our evaluation of
the studies in this systematic review, we suggest that future
studies should pay careful attention to points listed in Table
3. A more complete discussion and recommendations for
the collection and reporting of harms is described by
Ioannidis et al. [21] in an extension of the CONSORT
statement. Further consensus-driven approach could be
used to develop study guidelines for recording and report-
ing SAE in blood pressure treatment based on the input of
experts in the field.
Implications for clinical practice
The benefits of intensive antihypertensive treatments
include, primarily, reductions in the risks of ischemic heart
disease, left ventricular hypertrophy, chronic kidney dis-
ease, stroke and intracerebral haemorrhage. Nevertheless,
intensive treatment increases the risk of serious adverse
events such as hypotension, dizziness, syncope, injurious
falls and electrolyte abnormalities, compared with less
intensive treatments. Currently, no valid quantitative infor-
mation is available for physicians, due to the heterogeneous
results among published studies. Data are lacking on blood
pressure control in patients confined to institutions, patients
with symptomatic heart failure and patients with stroke. In
the light of our findings, treating physicians must balance
the risk of serious adverse events from a too intense
treatment with the well documented benefits of lowered
blood pressure [17,42,43].
Limitations and strengths
The main limitations of this review were the variable
definitions of serious adverse events and the nonuniform
recording methods. The main strength of this review is that
it was based on the PRISMA guidelines [18] and the SIGN
checklists [19], which facilitated a critical evaluation of the
included studies. Due to the heterogeneity of definitions
and methods for recording adverse events, we could not
conduct a synthesis of the results in a meta-analysis. To
compensate for this limitation, we provided a detailed,
qualitative review of the included studies. Another limita-
tion was that seven post hoc analyses were derived from the
same original study, the SPRINT Trial [6]. The results from
these studies cannot be considered as independent and
therefore do not give the same level of evidence as an
original study, but they do contribute useful information as
to the risks in different subgroups.
CONCLUSION
Compared with moderate blood pressure treatment, inten-
sive treatment was associated with higher rates of serious
adverse events in original studies. Moreover, significantly
more treatment-related adverse events were observed in
the intensive compared with themoderate treatment group.
However, it was difficult to determine whether adverse
events could be attributed to the treatment. A quantitative
synthesis was not possible due to stark differences in
baseline and serious adverse events reporting.
Further research must have precise, uniform definitions
of serious adverse events, in general, and of each single
adverse event, in particular. The methods of recording and
reporting need to be improved and standardized to facili-
tate the comparison of results.
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TABLE 3. Recommendations for recording and reporting of serious adverse event
Manuscript section Descriptor Descriptor details
Materials and methods section Define SAE and each type of SAE Description of SAE, grading and assessment of SAE
Define attribution of SAE Treatment-related or not, decision-process
Describe collection of SAE-data How, when, by whom, how many times
Results section Withdrawal due to SAEs In each study arm, timing, patient characteristics
Clear reporting of SAE Number of patients affected, number for each
type of SAEs, patient’s achieved BP at time
of SAE, recurrent SAEs, grading or severity
Discussion Balanced discussion of benefits–harms ratio
SAE, serious adverse event.
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